ERBB2 and breast carcinoma: Illustrating this, in previously treated HER2-low advanced breast cancer, trastuzumab deruxtecan achieved a complete response rate of 3.6%, accompanied by a median progression-free and overall survival of 9.9 and 23.4 months, respectively [33].